Molecure

Today, on #WorldHealthDay, we’re reminded that health is one of our most valuable assets - for ourselves, our loved ones and our global community 🌍 At #Molecure, we believe science has the power to drive real change. It enables us to develop innovative therapies that address unmet medical needs, improve lives and bring hope where it’s needed most. We’re proud to be making progress in the fight against sarcoidosis with #OATD01 and cancer with #OATD02, two diseases that significantly impact individuals, families and healthcare systems worldwide. On this day, we want to thank all those who, like us, are working to shape a better future for patients 💙

📣 Join us TODAY for an investor meeting dedicated to discussing the company's operational and financial situation for FY 2024 📊 During the meeting, we will present: 🔬 Progress in ongoing research programs 📈 Development plans for the coming quarters ⏰ 1:00 PM (CEST) PL: https://lnkd.in/d4Vbs-Fs ENG: https://lnkd.in/dXW2dQgA

#Molecure's financial report for 2024 is now available on our website 📈 Here are some of the highlights: 💊 Phase II clinical trial of #OATD01 - our lead clinical candidate has already been administered to multiple patients. The international #KITEstudy in pulmonary sarcoidosis is progressing dynamically, with active recruitment in five USA centers and the finalization of planned European sites 👩⚕ Advancing #OATD02 - dose escalation is ongoing to determine the pharmacologically active dose (PAD) and the maximum tolerated dose (MTD) 🔬 #USP7 inhibitor program - in collaboration with Avicenna Biosciences, we continue development using cutting-edge computational methods and AI 🧬 #mRNA platform - we have validated two therapeutic targets and confirmed successful inhibition of protein translation. In 2025, we plan to select two lead molecules and further develop expertise in advanced biophysical techniques 🤝 Partnering discussions on #OATD01 - we held dozens of meetings in 2024 with potential partners and are now engaged in advanced discussions Click here to view the full report (section "Raporty giełdowe") ➡ https://lnkd.in/djcwrXGn

#Molecure invites you to an investor meeting dedicated to discussing the company's operational and financial situation for FY 2024 📊 During the meeting, we will present: 🔬 Progress in ongoing research programs 📈 Development plans for the coming quarters 🗓️ Join us on April 2nd at 1:00 PM (CEST) PL: https://lnkd.in/d4Vbs-Fs ENG: https://lnkd.in/dXW2dQgA

Last week our Biologist - Scientist I, Joanna Grochowska, took part in the panel discussion "Project Scientist - different career paths in science" 👩⚕️👩🔬 The event was hosted by IMoL (Institute of Molecular Mechanisms and Machines) as part of UniStem Day 2025 - an international initiative dedicated to spreading reliable knowledge about stem cells. Taking place annually across Europe, UniStem Day aims to engage high school students through lectures and hands-on workshops designed to spark curiosity and inspire future scientists 💡 At #Molecure, we support initiatives that bring science closer to young minds! 🔬✨

Ciao from Milan! 👋 🇮🇹 Our team: CEO Marcin Szumowski, CSO Zbigniew Zaslona and Business Development Director Maurycy Zieliński, is currently attending #BIOEurope Spring 2025! 🔬 We are engaging in a series of strategic meetings and discussions, exploring new collaboration opportunities and connecting with industry leaders. If you are also attending, let’s connect! 🤝

We are excited to announce that #Molecure will be attending #BIOEurope Spring 2025, taking place from March 17–19 in Milan, Italy! 🇮🇹 Our team: CEO Marcin Szumowski, CSO Zbigniew Zaslona and Business Development Director Maurycy Zieliński, will be present to engage with industry leaders and explore strategic partnerships 🤝 BIO-Europe Spring is Europe's premier springtime partnering conference, bringing together leaders from the biotech and pharma industries to foster collaborations and drive innovation 🔬 We look forward to connecting with fellow innovators and exploring new opportunities to advance our mission. See you in Milan! 👋

Tomorrow we celebrate International Women’s Day! 🌸 At #Molecure, we honor and appreciate the incredible women in our team every single day. With 66% of our workforce being women, their talent, passion and innovation drive our mission to discover and develop groundbreaking therapies 👩⚕👩🔬 Let’s continue to support, empower and celebrate women who make a difference! 💜✨

Today, on Rare Disease Day, we want to raise awareness about pulmonary sarcoidosis - a rare, inflammatory disease that primarily affects the lungs, causing the formation of granulomas that can lead to lung scarring, breathing difficulties and a significant impact on patients' daily lives. Despite its severity, treatment options remain limited, often relying on corticosteroids, which can cause serious side effects. Patients need better solutions and at #Molecure, we are committed to finding them. Our lead drug candidate, #OATD01, is a first-in-class dual chitinase inhibitor that targets key pathways involved in the disease. Through the ongoing Phase II clinical trial #KITEstudy, we are evaluating its safety and effectiveness in treating pulmonary sarcoidosis. This international study is being conducted across multiple sites in Europe and the US, bringing us one step closer to a potential breakthrough in treatment. On this important day, we stand with the rare disease community! 💜

February is Cancer Prevention Awareness Month! 🌍 Every year, millions of lives are affected by cancer, but prevention and early detection can save lives. Here are some key steps you can take to lower your risk: 👉 Stay active – Regular physical activity helps maintain a healthy weight and reduces cancer risk. 👉 Eat smart – A balanced diet rich in fruits, vegetables and whole grains supports overall health. 👉 Avoid tobacco and limit alcohol – Smoking and excessive alcohol consumption are two of the leading causes of cancer.  👉 Protect your skin – Use sunscreen and avoid excessive sun exposure to lower the risk of skin cancer. 👉 Get screened – Early detection through regular check-ups significantly improves treatment outcomes. At #Molecure, we are committed to advancing cancer research. Our ongoing #OATD02 clinical trial is making continuous progress, bringing us closer to determining both the pharmacologically active dose and the maximum tolerated dose. This is a crucial step in developing a new, effective treatment for patients battling cancer. Together, we can fight cancer through awareness, prevention and innovation 💙